

Consensus or Controversy? Clinical Investigators Provide Perspectives on Biomarker Assessment and Related Treatment Decision-Making for Patients with Colorectal Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. According to the Phase III BEACON CRC study, which of the following was the most commonly reported Grade  $\geq 3$  adverse event for binimetinib/encorafenib/cetuximab triplet therapy in patients with BRAF-mutated metastatic colorectal cancer (mCRC)?
  - a. Stomatitis
  - b. Dry skin
  - c. Constipation
  - d. Diarrhea
2. According to the Phase III KEYNOTE-177 study, what was the approximate reduction in risk of progression or death in patients with microsatellite instability-high/mismatch repair-deficient (dMMR) mCRC treated with first-line pembrolizumab versus chemotherapy?
  - a. Less than 5%
  - b. 20%
  - c. 40%
  - d. 80%
  - e. Over 95%
3. The Phase II NICHE-2 study evaluating neoadjuvant nivolumab/ipilimumab for locally advanced dMMR colon cancer demonstrated which of the following outcomes?
  - a. Surgery was delayed in a significant fraction of patients due to autoimmune toxicity
  - b. Major pathological responses were observed in approximately one third of patients
  - c. Major pathological responses were observed in almost all patients
4. In the Phase III CodeBreak 300 study, treatment with which of the following yielded longer progression-free survival than standard treatment in patients with chemorefractory KRAS G12C-mutated mCRC?
  - a. Adagrasib monotherapy
  - b. Sotorasib monotherapy
  - c. Adagrasib + cetuximab
  - d. Sotorasib + panitumumab
5. Which gastrointestinal cancer subtype has the highest prevalence of KRAS mutations?
  - a. Small bowel cancer
  - b. Pancreatic cancer
  - c. Colorectal cancer
  - d. Hepatobiliary cancer